New Results
Optimization of the TeraTox assay for preclinical teratogenicity assessment
View ORCID ProfileManuela Jaklin, View ORCID ProfileJitao David Zhang, Nicole Schäfer, Nicole Clemann, View ORCID ProfilePaul Barrow, Erich Küng, View ORCID ProfileLisa Sach-Peltason, Claudia McGinnis, View ORCID ProfileMarcel Leist, View ORCID ProfileStefan Kustermann
doi: https://doi.org/10.1101/2021.07.06.451364
Manuela Jaklin
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
2Department for In Vitro Toxicology and Biomedicine Inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Germany
4Weleda AG, Arlesheim, Switzerland
Jitao David Zhang
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Nicole Schäfer
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Nicole Clemann
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Paul Barrow
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Erich Küng
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Lisa Sach-Peltason
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Claudia McGinnis
3University of Dundee, Drug Discovery Unit, Dundee, Scotland, UK
Marcel Leist
2Department for In Vitro Toxicology and Biomedicine Inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Germany
Stefan Kustermann
1Pharma Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann - La Roche, Switzerland
Posted July 07, 2021.
Optimization of the TeraTox assay for preclinical teratogenicity assessment
Manuela Jaklin, Jitao David Zhang, Nicole Schäfer, Nicole Clemann, Paul Barrow, Erich Küng, Lisa Sach-Peltason, Claudia McGinnis, Marcel Leist, Stefan Kustermann
bioRxiv 2021.07.06.451364; doi: https://doi.org/10.1101/2021.07.06.451364
Optimization of the TeraTox assay for preclinical teratogenicity assessment
Manuela Jaklin, Jitao David Zhang, Nicole Schäfer, Nicole Clemann, Paul Barrow, Erich Küng, Lisa Sach-Peltason, Claudia McGinnis, Marcel Leist, Stefan Kustermann
bioRxiv 2021.07.06.451364; doi: https://doi.org/10.1101/2021.07.06.451364
Subject Area
Subject Areas
- Biochemistry (11745)
- Bioengineering (8752)
- Bioinformatics (29200)
- Biophysics (14972)
- Cancer Biology (12096)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18308)
- Genetics (12245)
- Genomics (16803)
- Immunology (11869)
- Microbiology (28085)
- Molecular Biology (11592)
- Neuroscience (60969)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7340)
- Zoology (1651)